Advertisement

Paediatric MS

      Pediatric MS (i.e. disease onset before 18 years) shares many characteristics with adult-onset MS. However, children with MS have higher relapse and new MRI lesion rates than adults. They tend to have more severe relapses, with better recovery, but still develop disability at a younger age than adult-onset MS. Pediatric MS has the potential for irreversible central nervous system injury especially as it is still maturing. Differential diagnoses include ADEM, NMO and MOG-associated disease, among others. Very few drugs have been formally tested in that age group limiting the availability of safety and efficacy data. Treatment compliance in teenagers can be a particular problem. Discussing treatment options with teenagers and understanding their expectations and preferences may help pick a treatment that will have a better patient adherence. Over the past 10 years, physicians caring for patients with pediatric MS have increasingly used early intervention to limit disability progression and more aggressive treatment options. Interferons and glatiramer acetate have been the usual initial treatment choices for MS in children as open-label studies have shown they are safe. Other drugs such as natalizumab, fingolimod, fumaric acid, or rituximab/ocrelizumab are newer options. Limited information is available from retrospective studies regarding the safety and efficacy of these drugs in children except for fingolimod and teriflunomide that were studied in a randomized controlled trials in patients 10–17 years of age. Several ongoing trials are investigating the use of dimethyl fumarate and ocrelizumab in pediatric MS and will aid future treatment decisions including short-term safety information.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect